Keenova doses first patient in Phase 3 XIAFLEX hammer toe trial
MNK’s Keenova advances its podiatry pipeline by dosing the first patient in a Phase 3 trial of XIAFLEX (collagenase clostridium histolyticum) for hammer toe.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.